We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic. Source
No articles found.
Soliton, Inc. is a medical device company with a novel and proprietary platform te...
Soliton, Inc. is a medical device company with ...
Healing Budz is a social healing platform created with the purpose of spreading kn...
Healing Budz is a social healing platform creat...
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials compa...
PolarityTE is a commercial-stage biotechnology ...
CVBM Interests has designed a social media mobile app called Heart Rate Social. Th...
CVBM Interests has designed a social media mobi...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets ultrasoni...
Misonix, Inc. (Nasdaq: MSON) designs, develops,...
Join the National Investor Network and get the latest information with your interests in mind.